Related Experiment Video
Updated: May 2, 2026

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model
Published on: December 28, 2021
Studies on sensitivity of zebrafish as a model organism for Parkinson's disease: Comparison with rat model
Dinesh T Makhija1, Aarti G Jagtap1
1Department of Pharmacology, Bombay College of Pharmacy, Mumbai, Maharashtra, India.
Objective:
To determine the utility of zebra fish as an animal model for Parkinson's disease (PD) in comparison with rat model.
Materials And Methods:
MTT assay was performed on rat and zebrafish brain synaptosomal fractions using rotenone as a neurotoxic agent. Quercetin and resveratrol were used as standards to compare anti-apoptotic activity in both organisms. Catalepsy was induced in zebrafish by exposing them to haloperidol (9 μM) solution. Drug-treated groups were exposed to bromocriptine and pramipexole, 30 min prior to haloperidol exposure at the dose of 2, 5, and 10 μg/mL. Swimming speed, time spent in the bottom of the tank, and complete cataleptic time were evaluated to assess behavioral changes. In rats, catalepsy was induced using haloperidol (1.25 mg/kg i.p.). Drug-treated groups received bromocriptine (2.5 mg/kg.) and pramipexole (1 mg/kg) orally. Bar test, block test, and locomotor activity were carried out to assess behavioral changes.
Results:
Resveratrol and quercetin showed comparable inhibition of apoptosis in rats and zebrafish. In anti-cataleptic study, bromocriptine and pramipexole-treated groups showed significant difference (P < 0.05) in behavioral parameters as compared to haloperidol control group in both the experimental organisms. Results obtained from fish model were in correlation with rat model.
Conclusion:
Findings of the present study revealed that zebrafish model is highly sensitive and can be used for basic screening of drugs against PD.

